2025
Bristol Myers Squibb Marks Milestone with FDA Approval of Subcutaneous Opdivo Qvantig
Bristol Myers Squibb, Opdivo, subcutaneous administration, FDA approval, cancer treatment, immuno-oncology, PD-1 inhibitor.
Valo Health Suspends Development of OPL-0401, a ROCK Inhibitor for Diabetic Retinopathy, Following Phase 2 Study Results
Valo Health, OPL-0401, ROCK Inhibitor, Diabetic Retinopathy, Phase 2 Study, Clinical Trials, Drug Development
WuXi AppTec Divests Cell and Gene Therapy Units to Altaris in Strategic Shift
WuXi AppTec, Cell and Gene Therapy, Altaris, Strategic Divestment, Biosecure Act, Pharmaceutical Outsourcing
FDA Approves Subcutaneous Formulation of Bristol Myers’ Opdivo for Solid Tumor Indications
FDA approval, subcutaneous Opdivo, Bristol Myers Squibb, cancer treatment, immunotherapy, nivolumab, hyaluronidase
Axsome to Pursue FDA Approval for Alzheimer’s Agitation Treatment Despite Mixed Trial Results
Axsome Therapeutics, Alzheimer’s disease agitation, FDA approval, mixed trial data, AXS-05
BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn
BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements
Carecode Revolutionizes Brazilian Healthcare with AI-Powered Customer Service, Secures $4.3M Funding
Carecode, AI, Healthcare, Customer Service, Automation, Funding, Brazilian Healthcare